BIIB

Biogen Inc (BIIB)

Healthcare • NASDAQ$193.45+1.08%

Key Fundamentals
Symbol
BIIB
Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers - General
Price
$193.45
Daily Change
+1.08%
Market Cap
$28.56B
Trailing P/E
20.80
Forward P/E
11.67
52W High
$202.41
52W Low
$119.18
Analyst Target
$217.03
Dividend Yield
N/A
Beta
0.20
About Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-as

Company website

Research BIIB on Stk-Ai

Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.

Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.

Not financial advice. Terms · Privacy · ·

Loading...